Egalet ($EGLT) announced that its Guardian abuse-deterrence and drug delivery platform has been granted an additional patent by the U.S. Patent and Trademark Office. The patent is titled "Pharmaceutical Compositions Resistant to Abuse." It is the 14th U.S. patent covering the Guardian platform and its candidates. "This patent expands our intellectual property portfolio protecting products using our proprietary abuse-deterrent Guardian Technology," said Egalet CEO Bob Radie. "We will continue to strengthen our patent position covering our products which in some cases extends to 2033 to support our organic growth." According to the company website, "Guardian Technology utilizes injection molding to create a hard matrix and shell that is designed to be difficult to crush, grind, chew or dissolve and that turns to gel when exposed to water." Release